Dual-Targeted Agent Improves Advanced BTC Survival.

Interim phase 3 HARMONi-GI1 results show ivonescimab, a PD-1×VEGF bispecific antibody, significantly improves overall survival versus durvalumab with gemcitabine plus cisplatin in advanced biliary tract cancer.

• Why it matters: First-line options for advanced biliary tract cancer need better survival outcomes, and this trial addresses whether a dual-targeted approach outperforms PD-1 monotherapy plus the same chemotherapy.
• What they did: In the phase 3 HARMONi-GI1 trial, ivonescimab was combined with gemcitabine and cisplatin and compared against durvalumab plus the same chemotherapy backbone.
• The result: The interim results suggest ivonescimab-based therapy may become a new standard of care for first-line advanced biliary tract cancer, while patient selection and applicability beyond Chinese populations remain uncertain.